Dr. Lal PathLabs
- Home ›
- IN ›
- Healthcare
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. The last earnings update was 69 days ago. More info.
Add to Portfolio Compare Print
LALPATHLAB Share Price and Events
7 Day Returns
1 Year Returns
LALPATHLAB Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Dr. Lal PathLabs (LALPATHLAB) | 4% | 1.4% | 1.5% | 24.5% | 8.7% | - |
| IN Healthcare | 1.6% | 4% | -2.8% | -2.7% | -10.6% | 46% |
| IN Market | 1.7% | 2.7% | 5.8% | 0.1% | 41.6% | 73.3% |
1 Year Return vs Industry and Market
- LALPATHLAB outperformed the Healthcare industry which returned -2.7% over the past year.
- LALPATHLAB outperformed the Market in India which returned 0.1% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Dr. Lal PathLabs
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Dr. Lal PathLabs.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 15 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 14.5% |
| Perpetual Growth Rate | 10-Year IN Government Bond Rate | 7.6% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year IN Govt Bond Rate | 7.6% |
| Equity Risk Premium | S&P Global | 8.6% |
| Healthcare Unlevered Beta | Simply Wall St/ S&P Global | 0.72 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.715 (1 + (1- 35%) (0%)) |
0.809 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.81 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.809 * 8.6%) |
14.51% |
Discounted Cash Flow Calculation for NSEI:LALPATHLAB using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Dr. Lal PathLabs is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (INR, Millions) | Source |
Present Value Discounted (@ 14.51%) |
|
|---|---|---|---|
| 2019 | 1,770.50 | Analyst x8 | 1,546.16 |
| 2020 | 2,095.33 | Analyst x9 | 1,597.97 |
| 2021 | 2,637.88 | Analyst x8 | 1,756.82 |
| 2022 | 3,271.00 | Analyst x1 | 1,902.44 |
| 2023 | 3,668.00 | Analyst x1 | 1,863.02 |
| 2024 | 4,170.00 | Analyst x1 | 1,849.62 |
| 2025 | 4,637.58 | Est @ 11.21% | 1,796.37 |
| 2026 | 5,106.63 | Est @ 10.11% | 1,727.42 |
| 2027 | 5,583.84 | Est @ 9.34% | 1,649.51 |
| 2028 | 6,075.58 | Est @ 8.81% | 1,567.35 |
| Present value of next 10 years cash flows | ₹17,256.69 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= ₹6,075.58 × (1 + 7.55%) ÷ (14.51% – 7.55%) |
₹93,887.93 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= ₹93,887.93 ÷ (1 + 14.51%)10 |
₹24,220.80 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= ₹17,256.69 + ₹24,220.80 |
₹41,477.49 |
| Equity Value per Share (INR) |
= Total value / Shares Outstanding
= ₹41,477.49 / 83.34 |
₹497.68 |
| Calculation | Result | |
|---|---|---|
| Non-primary Listing Adjustment Factor |
1 share in NSEI:LALPATHLAB
represents 0.99934x
of
BSE:539524
(This could be a different class, a depositary receipt, a different currency, or all of these things.) |
0.99934x |
| Value per Share (Listing Adjusted, INR) |
= Value per Share (INR) x Listing Adjustment Factor
= ₹ 497.68 x 0.99934 |
₹497.35 |
| Value per share (INR) | From above. | ₹497.35 |
| Current discount | Discount to share price of
₹1,063.35
= -1 x (₹1,063.35 - ₹497.35) / ₹497.35 |
-113.8% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Dr. Lal PathLabs is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Dr. Lal PathLabs's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Dr. Lal PathLabs's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in INR | ₹23.36 |
| BSE:539524 Share Price ** | BSE (2019-04-18) in INR | ₹1064.05 |
| India Healthcare Industry PE Ratio | Median Figure of 23 Publicly-Listed Healthcare Companies | 23.87x |
| India Market PE Ratio | Median Figure of 2,735 Publicly-Listed Companies | 16.29x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Dr. Lal PathLabs.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = BSE:539524 Share Price ÷ EPS (both in INR) = 1064.05 ÷ 23.36 |
45.55x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Dr. Lal PathLabs is overvalued based on earnings compared to the IN Healthcare industry average.
- Dr. Lal PathLabs is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does
Dr. Lal PathLabs's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 45.55x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts |
19.2%per year |
| Asia Healthcare Industry PEG Ratio | Median Figure of 13 Publicly-Listed Healthcare Companies | 1.76x |
| India Market PEG Ratio | Median Figure of 584 Publicly-Listed Companies | 1.33x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 45.55x ÷ 19.2% |
2.37x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Dr. Lal PathLabs is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Dr. Lal PathLabs's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in INR | ₹106.12 |
| BSE:539524 Share Price * | BSE (2019-04-18) in INR | ₹1064.05 |
| India Healthcare Industry PB Ratio | Median Figure of 33 Publicly-Listed Healthcare Companies | 1.99x |
| India Market PB Ratio | Median Figure of 3,626 Publicly-Listed Companies | 1.12x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = BSE:539524 Share Price ÷ Book Value per Share (both in INR) = 1064.05 ÷ 106.12 |
10.03x |
* Primary Listing of Dr. Lal PathLabs.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Dr. Lal PathLabs is overvalued based on assets compared to the IN Healthcare industry average.
Value checks
We assess Dr. Lal PathLabs's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check) Dr. Lal PathLabs has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Dr. Lal PathLabs's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
- Dr. Lal PathLabs's earnings growth is expected to exceed the India market average.
- Dr. Lal PathLabs's revenue growth is expected to exceed the India market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NSEI:LALPATHLAB Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts | 19.2% |
| NSEI:LALPATHLAB Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts | 13.1% |
| India Healthcare Industry Earnings Growth Rate | Market Cap Weighted Average | 40.8% |
| India Healthcare Industry Revenue Growth Rate | Market Cap Weighted Average | 12.6% |
| India Market Earnings Growth Rate | Market Cap Weighted Average | 18.7% |
| India Market Revenue Growth Rate | Market Cap Weighted Average | 11.8% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
| Date (Data in INR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2024-03-31 | 24,022 | 4,520 | 1 | |
| 2023-03-31 | 20,980 | 4,018 | 1 | |
| 2022-03-31 | 18,323 | 3,571 | 1 | |
| 2021-03-31 | 16,304 | 2,918 | 2,918 | 14 |
| 2020-03-31 | 14,061 | 2,502 | 2,448 | 15 |
| 2019-03-31 | 12,133 | 2,121 | 2,022 | 15 |
| Date (Data in INR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 11,691 | 1,923 | |
| 2018-09-30 | 11,393 | 1,825 | |
| 2018-06-30 | 10,999 | 1,761 | |
| 2018-03-31 | 10,569 | 1,971 | 1,708 |
| 2017-12-31 | 10,100 | 1,617 | |
| 2017-09-30 | 9,548 | 1,565 | |
| 2017-06-30 | 9,389 | 1,586 | |
| 2017-03-31 | 9,124 | 1,713 | 1,546 |
| 2016-12-31 | 8,902 | 1,576 | |
| 2016-09-30 | 8,713 | 1,876 | |
| 2016-06-30 | 8,249 | 1,413 | |
| 2016-03-31 | 7,913 | 1,585 | 1,322 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
All data from Dr. Lal PathLabs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in INR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2024-03-31 | ||||
| 2023-03-31 | ||||
| 2022-03-31 | ||||
| 2021-03-31 | 35.09 | 40.00 | 30.30 | 12.00 |
| 2020-03-31 | 29.41 | 31.70 | 26.55 | 12.00 |
| 2019-03-31 | 24.31 | 26.20 | 22.47 | 12.00 |
| Date (Data in INR Millions) | EPS * |
|---|---|
| 2018-12-31 | 23.36 |
| 2018-09-30 | 22.20 |
| 2018-06-30 | 21.45 |
| 2018-03-31 | 20.85 |
| 2017-12-31 | 19.49 |
| 2017-09-30 | 18.88 |
| 2017-06-30 | 19.15 |
| 2017-03-31 | 19.02 |
| 2016-12-31 | 19.05 |
| 2016-09-30 | 20.34 |
| 2016-06-30 | 15.85 |
| 2016-03-31 | 16.09 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Dr. Lal PathLabs's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Dr. Lal PathLabs has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Dr. Lal PathLabs performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Dr. Lal PathLabs's year on year earnings growth rate has been positive over the past 5 years.
- Dr. Lal PathLabs's 1-year earnings growth exceeds its 5-year average (18.9% vs 15.2%)
- Dr. Lal PathLabs's earnings growth has exceeded the IN Healthcare industry average in the past year (18.9% vs -2.4%).
Earnings and Revenue History
All data from Dr. Lal PathLabs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in INR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 11,691.18 | 1,922.65 | 2,293.77 | |
| 2018-09-30 | 11,393.18 | 1,824.65 | 2,237.77 | |
| 2018-06-30 | 10,999.18 | 1,760.65 | 2,172.77 | |
| 2018-03-31 | 10,569.18 | 1,707.65 | 2,101.77 | |
| 2017-12-31 | 10,099.83 | 1,617.05 | 898.00 | |
| 2017-09-30 | 9,547.83 | 1,565.05 | 808.00 | |
| 2017-06-30 | 9,388.83 | 1,586.05 | 752.00 | |
| 2017-03-31 | 9,123.83 | 1,545.88 | 1,693.70 | |
| 2016-12-31 | 8,901.88 | 1,576.50 | 700.38 | |
| 2016-09-30 | 8,713.08 | 1,875.90 | 675.88 | |
| 2016-06-30 | 8,248.58 | 1,412.70 | 625.28 | |
| 2016-03-31 | 7,913.18 | 1,321.90 | 580.28 | |
| 2015-12-31 | 7,654.30 | 1,201.37 | 2,151.57 | 11.15 |
| 2015-03-31 | 6,595.90 | 907.67 | 497.25 | |
| 2014-03-31 | 5,579.47 | 762.71 | 1,755.40 | 9.54 |
| 2013-03-31 | 4,516.61 | 521.28 | 1,443.59 | 11.45 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Dr. Lal PathLabs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Dr. Lal PathLabs used its assets more efficiently than the IN Healthcare industry average last year based on Return on Assets.
- Dr. Lal PathLabs's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Dr. Lal PathLabs's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Dr. Lal PathLabs has a total score of 5/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Dr. Lal PathLabs's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Dr. Lal PathLabs's finances.
The net worth of a company is the difference between its assets and liabilities.
- Dr. Lal PathLabs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Dr. Lal PathLabs's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Dr. Lal PathLabs has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Dr. Lal PathLabs Company Filings, last reported 3 months ago.
| Date (Data in INR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 8,781.00 | 0.00 | 6,505.00 |
| 2018-09-30 | 8,781.00 | 0.00 | 6,505.00 |
| 2018-06-30 | 7,949.70 | 0.00 | 4,551.99 |
| 2018-03-31 | 7,949.70 | 0.00 | 4,551.99 |
| 2017-12-31 | 6,848.00 | 0.00 | 4,414.00 |
| 2017-09-30 | 6,848.00 | 0.00 | 4,414.00 |
| 2017-06-30 | 6,621.92 | 0.00 | 3,428.88 |
| 2017-03-31 | 5,979.57 | 0.00 | 3,397.16 |
| 2016-12-31 | 6,105.40 | 0.00 | 3,449.70 |
| 2016-09-30 | 6,105.40 | 0.00 | 3,449.70 |
| 2016-06-30 | 5,102.38 | 0.00 | 2,939.68 |
| 2016-03-31 | 5,102.38 | 0.00 | 2,742.74 |
| 2015-12-31 | |||
| 2015-03-31 | 3,433.76 | 0.00 | 1,861.02 |
| 2014-03-31 | 2,333.33 | 16.03 | 1,142.52 |
| 2013-03-31 | 1,636.73 | 12.28 | 762.34 |
- Dr. Lal PathLabs has no debt.
- Dr. Lal PathLabs has no debt compared to 5 years ago when it was 0.7%.
- Dr. Lal PathLabs has no debt, it does not need to be covered by operating cash flow.
- Dr. Lal PathLabs has no debt, therefore coverage of interest payments is not a concern.
Financial health checks
We assess Dr. Lal PathLabs's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Dr. Lal PathLabs has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Dr. Lal PathLabs's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
₹2,000 of
Dr. Lal PathLabs
shares you are expected to receive
₹10
in your first year as a dividend.
Dividend Amount
- Dr. Lal PathLabs's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.49%).
- Dr. Lal PathLabs's dividend is below the markets top 25% of dividend payers in India (1.92%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
| India Healthcare Industry Average Dividend Yield | Market Cap Weighted Average of 10 Stocks | 0.7% |
| India Market Average Dividend Yield | Market Cap Weighted Average of 1399 Stocks | 1.3% |
| India Minimum Threshold Dividend Yield | 10th Percentile | 0.3% |
| India Bottom 25% Dividend Yield | 25th Percentile | 0.5% |
| India Top 25% Dividend Yield | 75th Percentile | 1.9% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in ₹) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2024-03-31 | ||
| 2023-03-31 | ||
| 2022-03-31 | ||
| 2021-03-31 | 5.35 | 10.00 |
| 2020-03-31 | 4.81 | 10.00 |
| 2019-03-31 | 4.42 | 9.00 |
| Date (Data in ₹) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2018-11-29 | 5.500 | 0.548 |
| 2018-05-14 | 4.500 | 0.490 |
| 2017-11-09 | 3.200 | 0.364 |
| 2017-05-12 | 3.400 | 0.413 |
| 2017-02-02 | 2.600 | 0.268 |
| 2016-07-29 | 2.450 | 0.227 |
| 2016-05-30 | 2.450 | 0.262 |
| 2016-02-15 | 0.000 | 0.000 |
| 2015-12-23 | 0.000 | 0.000 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Whilst dividend payments have been stable, Dr. Lal PathLabs has been paying a dividend for less than 10 years.
- Dividend payments have increased, but Dr. Lal PathLabs only paid a dividend in the past 3 years.
Income/ dividend checks
We assess Dr. Lal PathLabs's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Dr. Lal PathLabs afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Dr. Lal PathLabs has a total score of 3/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | ₹29,720,187 |
| AGE | 53 |
| TENURE AS CEO | 11 years |
CEO Bio
Dr. Om Prakash Manchanda, also known as Om, has been the Chief Executive Officer of Dr. Lal PathLabs Pvt. Ltd. since April 01, 2008 and has been its Whole Time Director since February 01, 2011. He has a diverse experience of over 24 years across sales, marketing and general management functions in business sectors such as FMCG, agri-biotech products, consumer healthcare and medical diagnostics. Dr. Manchanda served as the Chief Operating Officer of Dr. Lal PathLabs Pvt. Ltd. He joined Dr Lal PathLabs in 2005. He led the International & Innovation group of the Consumer Healthcare Division at Ranbaxy. He was part of the senior management team responsible for launching Ranbaxy’s foray into consumer healthcare. Prior to Ranbaxy, he worked at Monsanto as the head of Sales and Marketing, where his team successfully launched the company’s first ever biotech product Bt-Cotton. He served at Hindustan Unilever for about 10 years. He received in-depth exposure in consumer product sales, distribution and marketing. He cherishes the memory of how at Unilever, as the Senior Brand Manager - Innovation, he had led the designing and launching of a tea-based beverage at HLL, which won Unilever's Global Innovation Award. Dr. Manchanda considers that award special among the several awards he had received at Unilever. He has been an Independent Director at Prataap Snacks Limited since July 05, 2016. He is an avid reader of management books with his favorite authors being Steven Covey, Jack Welch, Peter M Senge and John Philip Jones. He has an MBA from the Indian Institute of Management, Ahmadabad. Dr. Manchanda is also a Doctor in Veterinary Sciences from HAU, Hisar. Dr. Manchanda holds a bachelor's degree in veterinary science and animal husbandry Agricultural University from the Haryana Agricultural University and a post graduate diploma in management (agriculture) from the Indian Institute of Management, Ahmadabad.
CEO Compensation
- Om's compensation has been consistent with company performance over the past year.
- Om's remuneration is about average for companies of similar size in India.
Management Team Tenure
Average tenure and age of the Dr. Lal PathLabs management team in years:
- The tenure for the Dr. Lal PathLabs management team is about average.
Management Team
Arvind Lal
Chairman & MD
₹22M
69
Om Manchanda
CEO & Whole Time Director
₹30M
53
11 yrs
Rajat Kalra
Legal Head
₹3M
41
3.8 yrs
Vandana Lal
Whole-Time Director
₹18M
61
C. A. Ved Goel
Chief Financial Officer
0.7 yrs
Bharath Uppiliappan
Chief Operating Officer
1.3 yrs
Munender Soperna
Chief Information Officer
4.8 yrs
Manoj Sahay
Chief Marketing & Strategy Officer
1.8 yrs
Manoj Garg
Chief Human Resources Officer
49
4.5 yrs
Shankha Banerjee
Chief Growth Officer
4.7 yrs
Board of Directors Tenure
Average tenure and age of the Dr. Lal PathLabs board of directors in years:
- The tenure for the Dr. Lal PathLabs board of directors is about average.
Board of Directors
Om Manchanda
CEO & Whole Time Director
₹30M
53
8.2 yrs
Vandana Lal
Whole-Time Director
₹18M
61
24.2 yrs
Sunil Varma
Independent Non-Executive Director
₹2M
74
3.7 yrs
Arvind Lal
Chairman & MD
₹22M
69
Saurabh Srivastava
Independent Non-Executive Director
₹2M
71
3.7 yrs
Rahul Sharma
Non Executive Director
58
13.8 yrs
Anoop Singh
Independent Non-Executive Director
₹1M
47
3.7 yrs
Harneet Chandhoke
Independent Non-Executive Director
₹2M
52
3.7 yrs
Somya Satsangi
Independents Director
0.2 yrs
Who owns this company?
Recent Insider Trading
- Dr. Lal PathLabs insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (₹) | Value (₹) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 27. Mar 19 | Sell | Bharath Uppiliappan | Individual | 22. Mar 19 | 26. Mar 19 | -1,250 | ₹1,075.40 | ₹-1,344,252 | ||
| 11. Mar 19 | Sell | Reena Nakra | Individual | 06. Mar 19 | 06. Mar 19 | -1,000 | ₹1,018.98 | ₹-1,018,977 | ||
| 22. Feb 19 | Sell | Manoj Garg | Individual | 15. Feb 19 | 21. Feb 19 | -1,032 | ₹1,034.60 | ₹-1,067,704 | ||
| 21. Feb 19 | Sell | Neelum Tripathi | Individual | 19. Feb 19 | 19. Feb 19 | -1,000 | ₹1,024.92 | ₹-1,024,924 | ||
| 15. Feb 19 | Sell | Munender Soperna | Individual | 11. Feb 19 | 13. Feb 19 | -2,975 | ₹1,040.88 | ₹-3,096,611 | ||
| 15. Feb 19 | Buy | Munender Soperna | Individual | 13. Feb 19 | 13. Feb 19 | 50 | ₹1,026.85 | ₹51,342 | ||
| 05. Dec 18 | Sell | Neelum Tripathi | Individual | 03. Dec 18 | 03. Dec 18 | -2,000 | ₹878.78 | ₹-1,757,551 | ||
| 24. Sep 18 | Sell | Shankha Banerjee | Individual | 29. Aug 18 | 29. Aug 18 | -500 | ₹1,114.00 | ₹-557,000 | ||
| 31. Aug 18 | Sell | Neelum Tripathi | Individual | 29. Aug 18 | 29. Aug 18 | -1,500 | ₹1,100.91 | ₹-1,651,372 | ||
| 29. Aug 18 | Sell | Shankha Banerjee | Individual | 24. Aug 18 | 27. Aug 18 | -3,000 | ₹1,046.77 | ₹-3,140,308 | ||
| 29. Aug 18 | Sell | Manoj Garg | Individual | 27. Aug 18 | 27. Aug 18 | -1,500 | ₹1,060.00 | ₹-1,590,000 | ||
| 23. Aug 18 | Sell | Bharath Uppiliappan | Individual | 17. Aug 18 | 17. Aug 18 | -200 | ₹1,004.00 | ₹-200,800 | ||
| 23. Aug 18 | Sell | Shankha Banerjee | Individual | 17. Aug 18 | 21. Aug 18 | -1,500 | ₹1,025.33 | ₹-1,538,000 | ||
| 04. Jul 18 | Sell | Manoj Garg | Individual | 25. Jun 18 | 29. Jun 18 | -1,500 | ₹957.97 | ₹-1,436,950 | ||
| 02. Jul 18 | Sell | Shankha Banerjee | Individual | 28. Jun 18 | 29. Jun 18 | -1,500 | ₹940.00 | ₹-1,410,000 | ||
| 29. Jun 18 | Sell | Neelum Tripathi | Individual | 28. Jun 18 | 28. Jun 18 | -2,000 | ₹930.01 | ₹-1,860,022 | ||
| 25. Jun 18 | Sell | Dilip Bidani | Individual | 21. May 18 | 22. Jun 18 | -3,000 | ₹910.33 | ₹-2,731,000 | ||
| 20. Jun 18 | Sell | Om Manchanda | Individual | 18. Jun 18 | 18. Jun 18 | -100,000 | ₹863.01 | ₹-86,300,716 | ||
| 31. May 18 | Sell | Om Manchanda | Individual | 29. May 18 | 31. May 18 | -28,070 | ₹866.94 | ₹-24,335,071 | ||
| 18. May 18 | Buy | C. A. Ved Goel | Individual | 14. May 18 | 14. May 18 | 8,866 | ₹110.80 | ₹982,353 | ||
Management checks
We assess Dr. Lal PathLabs's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Dr. Lal PathLabs has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) 0.5% Dividend Yield Looks Pretty Interesting
Unfortunately, one common occurrence with dividend companies is for investors to be enticed in by the seemingly attractive yield, and lose money when the company has to cut its dividend payments.. … Many of the best dividend stocks typically start out paying a low yield, so we wouldn't automatically cut it from our list of prospects.! … Before you buy any stock for its dividend however, you should always remember Warren Buffett's two rules: 1) Don't lose money, and 2) Remember rule #1
Simply Wall St - – Full articleIs Dr. Lal PathLabs Limited’s (NSE:LALPATHLAB) 29% ROCE Any Good?
Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … Return On Capital Employed (ROCE): What is it? … ROCE measures the 'return' (pre-tax profit) a company generates from capital employed in its business.
Simply Wall St - – Full articleShould You Be Pleased About The CEO Pay At Dr. Lal PathLabs Limited's (NSE:LALPATHLAB)
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Om Manchanda's Compensation Compare With Similar Sized Companies. … While we always look at total compensation first, we note that the salary component is less, at ₹28m
Simply Wall St - – Full articleShould You Be Tempted To Sell Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Because Of Its P/E Ratio?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … That is equivalent to an earnings yield of about 2.2%. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleDoes Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) 19% Earnings Growth Make It An Outperformer?
For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. … Did LALPATHLAB's recent earnings growth beat the long-term trend and the industry. … LALPATHLAB's trailing twelve-month earnings (from 31 December 2018) of ₹1.9b has.
Simply Wall St - – Full articleHow Much Are Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Insiders Taking Off The Table?
It's quite normal to see company insiders, such as board members, trading in company stock, from time to time. … In the last twelve months, the biggest single sale by an insider was when CEO & Whole Time Director Om Manchanda sold ₹86m worth of shares at a price of ₹863 per share. … As a general rule we consider it to be discouraging when insiders are selling below the current price
Simply Wall St - – Full articleA Holistic Look At Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Help shape the future of investing tools and you could win a $250 gift card! … Building up an investment case requires looking at a stock holistically. … Lal PathLabs Limited (NSE:LALPATHLAB) due to its excellent fundamentals in more than one area.
Simply Wall St - – Full articleDo Directors Own Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Shares?
Generally speaking, as a company grows, institutions will increase their ownership. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … Our analysis of the ownership of the company, below, shows that.
Simply Wall St - – Full articleIs Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Spending Too Much Money?
Lal PathLabs’s cash flow health and the risk-return concept based on the stock’s cash flow yield, using the most recent financial data. … This will help you think about the company from a cash perspective, which is a crucial factor to investing. … Free cash flow (FCF) is the amount of cash Dr
Simply Wall St - – Full articleIs Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Excessively Paying Its CEO?
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … Lal PathLabs Limited has a market capitalization of ₹80b, and pays its CEO total annual compensation worth ₹30m. … We looked at a group of companies with market capitalizations from ₹28b to ₹112b, and the median CEO compensation was ₹24m.
Simply Wall St - – Full articleCompany Info
Description
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company offers a range of diagnostic and related healthcare tests and services for use in core testing and patient diagnosis, as well as in the prevention, monitoring, and treatment of disease and other health conditions. Its customers include individual patients, hospitals, other healthcare providers, and corporate customers. As of May 14, 2018, the company owned and operated a National Reference Laboratory in New Delhi, as well as 191 other clinical laboratories, 2,153 patient service centers, and approximately 5,624 pickup points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurgaon, India.
Details
| Name: | Dr. Lal PathLabs Limited |
| LALPATHLAB | |
| Exchange: | NSEI |
| Founded: | 1949 |
| ₹87,683,707,881 | |
| 83,341,610 | |
| Website: | http://www.lalpathlabs.com |
| Address: |
Dr. Lal PathLabs Limited Tower B, SAS Tower, 12th Floor, Gurgaon, Haryana, 122001, India |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| BSE | 539524 | Equity Shares | Mumbai Stock Exchange | IN | INR | 23. Dec 2015 | |
| NSEI | LALPATHLAB | Equity Shares | National Stock Exchange of India | IN | INR | 23. Dec 2015 |
Number of employees
Current staff
Industry
| Health Care Services | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/18 13:03 |
| End of day share price update: | 2019/04/18 00:00 |
| Last estimates confirmation: | 2019/04/08 |
| Last earnings filing: | 2019/02/08 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/03/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
